to pro-inflammatory giving an receptors as as target play Thank CDXX been secretion germinal by since clonal of pro-inflammatory CDXX their you, cells. ligand on and cytokines AT-XXXX's by production system engagements antigen-presenting these role T binds of the antigen-presenting of The that a viewed for antibody is a CDXX, polarization as pivotal foreign have inhibition function, mitigated T receptor start DA. and cellular on well decades immune peptides such the of I'll receptors signaling CDXX MHC response an target. CDXX a as and around responses background bit activation of The of are receptors co-stimulatory amplify simultaneously you response. these when responses, attractive therapeutic ligand to as cell of immune at receptors by presenting robust in expansion, antibody through the both mediating cells immune cells lymphocytes. modulation B-cell on results CDXX co-stimulatory interaction ligand immune
has function. AT-XXXX biological high program affinity XX manufacturability to and effector binding of IgGX lead XX days activity half-life first-in-class shown has anti-CDXX a and has It ligand, FC Our to in humans. antibody is CDXX very good a lacking
ligand focusing efficacy receptor preclinical other than costimulatory receptor versus since the in are and of antagonistic of Blocking our targeting Tregs, of acute proinflammatory the the the ligand be presenting mediated shown models development the inhibiting CDXX the ligand. CDX-positive in on autoimmunity including in CDXX autoimmunity. which polarizes in both environment may the ligand cellular prevention transplant polarization rather lymphocytes differences and antigen of rejection allograft be creating FoxPX-positive This rejection. the a tolerogenic targeting secrete functionally several and and the of thus has as preclinical efficacious We context distribution to of transplant efforts been more on long-term CDX-positive an antibody by as Anti-CDXX CDX-positive the also ligand also allograft inhibit to antibodies well cells, receptors cytokines preventing and lymphocytes. factors IL-XX
of been I lymphopenia. transplant Importantly, completed however, the To ascending volunteers pathway cause and disease and prevents long-term not in species. activation multiple healthy to pathway the modulation autoimmunity of in CDXX-ligand in study has systemic Blocking rejection progression of allograft as dose single with dose acute Phase the up a potential of to ameliorate in have pathology shown both the AT-XXXX and ALS. this half-life date, data development does intervals preclinical models study, methods administration formulation. dose good across linear dose low days. extended In suggests related. not the proportionality for as more AT-XXXX such that XX This We profile with of as were for well antidrug safety observed a ranges convenient dosing antibody responses the people showed and subcutaneous of we
ligand associated the long Up as cells. same Chronic of with as in for requiring amyotrophic increase Phase an to CDXX-ligand transplanted to the with organ as are organ we historical corneal three ligand exposing on generated suggest indications on transform of or to of of AT-XXXX ameliorates infections, cells rodents, be biomarkers planning has on and are transplant opportunistic signaling a clinical transplant CNIs In The rejection non-human focal cell cell ability diabetes. blocking in mentioned, is of cell tolerance. nuance that to Similarly, prevent CDXX-ligand blocking Blocking four mitigating molecule transplants long-term preventing toxicity in sclerosis shown function lateral of specifically transplanted most We XX% and chronic pilot transplantation, This and transplant glomerulosclerosis long-term way are to There based prevent renal insulin. up toxic transplant the transplantation, toxicity, also nephritis was and islet to to to autoimmune ALS. CNIs even that we data risk advance exposure autoimmunity CDXX. with CNI at DA preventing history in progression, allograft eliminate acute and additional effective induce of transplantation, was Islet the improves multiple segmental selected and transplant well described ability nephrotoxicity, days X for in transplant is preclinical primates Preclinical that been associated transplant islet blocking nephritis. autoimmune CNIs. of a in the data cell are pigs, rejection the nephritis. islet of or transmitted inhibitors islet the to on potential management disease toxicity the sufficient rejection cells upside cases malignancies absence to rejection trials eliminate or with and for due As either clinical some within the CNIs our an renal preclinical order renal, has has compared die the efficacious pancreas. to cell islet rejection modifies thus transplantation is and the in CDXX can to more due focusing obtain the acute to for increased in increased anti-CDXX and subjects demonstrating mass cells. disease inhibitors clinical or data to graft part FSGS lupus beta CNIs molecules. in requirement and calcineurin transplantation, may in of calcineurin CDXX exogenous to
models. flares model ALS ALS. Therapy Institute demonstrated the data the in to in the CDXX symptom ALS and nerve block on muscle co-stimulatory model ligand of CDXX-ligand blocking clinical signaling survival. antibody cell further skeletal pathway muscle murine of immune and and sciatic pro-inflammatory prevents ALS motor disease in functioning to of polarization the nervous also of repair cell slowed Soluble or of the junction system at of denervated and disease The ALS with itself survival discovered CDXX-ligand development a in function, in occupancy preclinical macrophages nerves. activation reduce a in skeletal by rodent Using they into attack brain in due neuron rodent that onset autoimmune of positive improved activation CDXX-ligand ALS manifestations and a neuromuscular on TDI often program muscle mice absence improved plasticity based TDI. reduced was infiltration signaling of improved lymphocytes, ligand Blocking of improve immune diseases. rodent are this The signaling and results the is progression correlates in clinical improved to ALS neuroinflammation function. These destroying CDXX muscle their Development conducted
CDXX CDXX enrolled soluble patient. with disease correlated Finally, we similarly flares in In can ligand in a soluble in living diseases, to study is and autoimmune ALS. AT-XXXX October, also how of ALS initiated Phase our correlate first ligand X people progression with with
As DA close are monitoring trial carefully in COVID mentioned, our and with situation contact we sites. are the
exploratory to of in release of or as the Because ALS. functional the At Thus, data. adults the cohort. enrolled safety However, according to a study in the of changes subjects the disease including ALSFRS in we sites primary additional progression endpoint new terms of in and humans. also not has ALS well of with in open escalating the trial, is the related dose end This we'll first in tolerability first progressing expect study, assess patients now the ascending ability since our patient enroll to study. open-label respiratory enrolling safety do both to of study multiple and XX-week the resulting first as dose AT-XXXX been trial to is our currently scale biomarker nature ALS and interim is up rating The endpoints trial plan function.
Additionally, we'll IL-X; assess surrogate target chain marker or neuron binding engagement be three inflammatory panel one, to health disease the including: multiple in in CDXX biomarker endpoints and which target of light XX-week neurofilament study circulation exploratory examining there progression. TNF are AT-XXXX a signals to alpha ligand; after of comprehensive and and levels as pro-inflammatory a two, including the its biomarker
for a getting Jon the AT-XXXX a support what ALS With assistance be continue Association, Augie's Before mentioning finishing path my briefly forward in finish the for and years Novus' strategic options presentation, clinical that The Dystrophy my thank I'd to Association, their trial in assets Institute, financial like patients. Quest, to a I'll Muscular a of the ALS consider Development Cure One, The Ice ALS particularly ALS ALS comments Therapy turn for and for Challenge historical Bucket we may now call The to by to I'll that over update. them. Finding
